Eikon Therapeutics Releases Seven Abstracts for 2026 ESMO Congress in Madrid

Eikon Therapeutics published seven full-text abstracts covering four clinical candidates for the 2026 European Society for Medical Oncology Congress in Madrid, Spain, which begins on October 23, 2026. The company announced the abstracts on October 18, 2026, according to TradingView.

What Eikon's Seven ESMO Abstracts Cover

Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing oncology medicines, based in Millbrae, California. The abstracts cover EIK1001, EIK1003, EIK1004 and EIK1005.

For EIK1001, a TLR7/8 dual-agonist, the abstracts include updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001 plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer, and a Phase 2/3 study design for EIK1001 with pembrolizumab and chemotherapy in stage 4 NSCLC, called TeLuRide-008.

EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, appears in updated cohort data from an ongoing Phase 1/2 study as monotherapy and with chemotherapy in advanced solid tumors, and in initial data from a Phase 1/2 study with abiraterone in metastatic prostate cancer.

EIK1004, a highly selective CNS-penetrant PARP1 inhibitor, has initial results from an ongoing Phase 1/2 study in advanced solid malignancies. EIK1005, a Werner helicase inhibitor, has preliminary safety, tolerability and pharmacokinetic data and a Phase 1/2 study design as monotherapy and with pembrolizumab in advanced solid tumors, including MSI-H or dMMR tumors.

"We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon.

Eikon's Funding and Pipeline Records

Eikon Therapeutics priced an upsized initial public offering of 21,177,600 shares at $18.00 on Nasdaq under the ticker EIKN in February 2026, raising approximately $381 million in gross proceeds, according to akta.pro company records. The same records list more than $1.1 billion raised privately since its 2019 founding, including a $148 million Series A in May 2021, a $517.8 million Series B in January 2022, a $106 million Series C in June 2023 and a $350.7 million Series D in February 2025.

Eikon dosed the first patient in a Phase 1/2 trial of EIK1005 in February 2026, the first clinical candidate advanced from its internal single molecule tracking discovery platform. Merck & Co. supplies pembrolizumab for the TeLuRide-006 Phase 2/3 trial of EIK1001 in advanced melanoma, with the first patient enrolled in May 2025.

Eikon's Run-Up to the Madrid Congress

Eikon Therapeutics reported a second-quarter GAAP loss of $1.63 per share, missing analysts' expectations by $0.03, and held $531.2 million in cash, cash equivalents and marketable securities projected to fund operations into the second half of 2027, Seeking Alpha reported in August 2026. The company held a conference call with Cantor Fitzgerald analysts and Dr. Timothy Yap of MD Anderson in August 2026 to discuss PARP1 biology and next-generation PARP inhibitors, Seeking Alpha reported. CEO Roger Perlmutter and CFO Alfred Bowie appeared at Morgan Stanley's 24th Annual Global Healthcare Conference on September 15, 2026, Seeking Alpha reported.

Eikon's ESMO Presentation Dates

EIK1003, EIK1004 and EIK1005 presentations are scheduled for October 23, 2026, from 15:15 to 16:00. EIK1001 presentations are scheduled for October 26, 2026, from 12:00 to 12:45.